India Over the Counter Drugs Market Demand, Size and Competitive Analysis | TechSci Research

India Over The Counter Drugs Market was valued at USD 5677.32 Million in 2024 and is anticipated to reach USD 8672.40 Million by 2030, with a CAGR of 7.13% during 2025-2030. <table><tr><td>Pages</td><td>80</td></tr> <tr><td>Market Size</td><td>2024: USD 5677.32 Million</td></tr> <tr><td>Forecast Market Size</td><td>2030: USD 8672.40 Million</td></tr> <tr><td>CAGR</td><td>2025-2030: 7.13%</td></tr> <tr><td>Fastest Growing Segment</td><td>Cold, Cough & Flu</td></tr> <tr><td>Largest Market</td><td>South India</td></tr> <tr><td>Key Players</td><td>1.Cipla Limited2.Sun Pharmaceutical Industries Ltd. 3.Lupin Limited4.GlaxoSmithKline Pharmaceuticals Limited5.Dabur India Limited6.Abbott India Limited7.Dr. Reddy’s Laboratories Ltd.8.Emami Limited9.Reckitt (India) Ltd.10.Johnson & Johnson Pvt. Ltd.</td></tr> </table>

2024年，印度非处方药市场规模达到56.7732亿美元，预计到2030年将增至86.724亿美元，期间（2025-2030年）的复合年增长率预计为7.13%。详见表格：

<table>
<tr>
<td>页数</td>
<td>80页</td>
</tr>
<tr>
<td>市场规模</td>
<td>2024年：56.7732亿美元</td>
</tr>
<tr>
<td>预测市场规模</td>
<td>2030年：86.724亿美元</td>
</tr>
<tr>
<td>复合年增长率（CAGR）</td>
<td>2025-2030年：7.13%</td>
</tr>
<tr>
<td>增长最快的细分市场</td>
<td>感冒、咳嗽及流感</td>
</tr>
<tr>
<td>最大市场</td>
<td>南印度</td>
</tr>
<tr>
<td>主要参与者</td>
<td>1. Cipla Limited 2. Sun Pharmaceutical Industries Ltd. 3. Lupin Limited 4. GlaxoSmithKline Pharmaceuticals Limited 5. Dabur India Limited 6. Abbott India Limited 7. Dr. Reddy’s Laboratories Ltd. 8. Emami Limited 9. Reckitt (India) Ltd. 10. Johnson & Johnson Pvt. Ltd.</td>
</tr>
</table>